Spine BioPharma

Executive Summary

Spine BioPharma is a clinical-stage biotechnology company developing non-surgical, non-opioid therapies for degenerative spine diseases. Its lead candidate, SB-01, is an intradiscal injection for degenerative disc disease currently in Phase 3 trials. Degenerative disc disease affects millions worldwide, and current treatment options are limited to surgery or opioids, both with significant drawbacks. SB-01 aims to slow disease progression, reduce pain, and restore function, addressing a large unmet need. The company is based in San Diego and was founded in 2016. With SB-01 advancing through pivotal studies, Spine BioPharma represents a potential first-in-class therapy for a condition with no approved disease-modifying treatments. The market opportunity is substantial, and the non-invasive approach could disrupt current standard of care. However, as a private company with limited disclosed financials, the path to commercialization remains dependent on successful trial outcomes and funding.

Upcoming Catalysts (preview)

• 2027Phase 3 Top-Line Data for SB-0150% success
• 2026Potential Partnership or Licensing Deal40% success